Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 15/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19498794 | 0.93 | SIGMAR1 (0.89) | SIGMAR1HTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL8091471 | 0.87 | SIGMAR1 (1.00) | SIGMAR1MEN1KMT2A | |
| SCHEMBL21985949 | 0.87 | SIGMAR1 (1.00) | SIGMAR1MEN1KMT2A | |
| SCHEMBL22043526 | 0.87 | SIGMAR1 (1.00) | SIGMAR1MEN1KMT2A | |
| SCHEMBL19469329 | 0.87 | SIGMAR1 (1.00) | SIGMAR1MEN1KMT2A | |
| SCHEMBL19469330 | 0.87 | SIGMAR1 (1.00) | SIGMAR1MEN1KMT2A | |
| SCHEMBL22043276 | 0.87 | SIGMAR1 (1.00) | SIGMAR1MEN1KMT2A | |
| SCHEMBL22431580 | 0.86 | SIGMAR1 (0.78) | SIGMAR1HTTSMN1; SMN2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL19469328 | 0.86 | SIGMAR1 (0.97) | SIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL19469327 | 0.86 | SIGMAR1 (0.97) | SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200290948-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2020-09-17 | — | — | US | disclosed |
| US-20200237688-A1 | VESICULAR MONOAMINE TRANSPORTER-2 LIGANDS AND THEIR USE IN THE TREATMENT OF PSYCHOSTIMULANT ABUSE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2020-07-30 | — | — | US | disclosed |
| US-10668030-B2 | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20170304227-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2017-10-26 | — | — | US | disclosed |
| US-20170304227-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290948-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | SLC18A2, SLC6A2, SLC6A3 | SIGMAR1 109/4885HTT 276/4885SMN1; SMN2 1291/4885 |
| US-10668030-B2 | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | SLC18A2, SLC6A2, SLC6A3 | SIGMAR1 109/4885HTT 276/4885SMN1; SMN2 1291/4885 |
| US-20200237688-A1 | VESICULAR MONOAMINE TRANSPORTER-2 LIGANDS AND THEIR USE IN THE TREATMENT OF PSYCHOSTIMULANT ABUSE | SLC18A2, SLC6A2, SLC6A3 | SIGMAR1 109/4885HTT 276/4885SMN1; SMN2 1291/4885 |
| US-20170304227-A1 | Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse | SLC18A2, SLC6A2, SLC6A3 | SIGMAR1 109/4885HTT 276/4885SMN1; SMN2 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.